USANA Earnings Call: Retail Push Amid Margin Strain

USANA Health Sciences Inc ((USNA)) has held its Q4 earnings call. Read on for the main highlights of the call.

USANA Health Sciences Inc.’s latest earnings call painted a cautiously optimistic picture, blending solid operational wins with notable financial risks. Management struck a confident tone around venture brands Hiya and Rise Wellness and a 4% net sales growth target for fiscal 2026, yet acknowledged pressure on margins, taxes, and working capital that could temper investor enthusiasm.

Fiscal 2026 Net Sales Guidance

USANA guided to consolidated net sales growth of about 4% at the midpoint for fiscal 2026, even with one fewer week than fiscal 2025. The outlook leans heavily on execution in newer channels and brands, suggesting management believes its growth initiatives can offset lingering weakness in the core business.

Retail Expansion and Distribution Wins

Venture brands are rapidly broadening their retail presence, with Hiya launching into Target in April and expanding into Canada and the U.K. Rise Wellness has secured distribution in all Costco stores and is rolling out in Target, while management indicated discussions with additional major U.S. retailers that could further lift revenue.

Inventory Build to Support Growth

Inventories climbed $35 million year over year to $107 million, a 48% increase, with roughly 80% tied to Rise Wellness and Hiya. The company expects inventory to remain elevated through fiscal 2026 as it supports retailer launches, international expansion, and raw material stockpiling ahead of in‑house manufacturing.

Leadership and Strategic Refocus

Kevin Guest’s return as CEO, while remaining Chairman, signals a return to experienced leadership and a sharper strategic lens. His agenda centers on omnichannel expansion, product innovation, technology modernization, operational efficiencies, and a stronger culture of accountability across the organization.

Cost Realignment and Savings

USANA undertook a cost realignment that impacted about 10% of its workforce and is expected to generate roughly $10 million in net annual savings, mainly within SG&A. Management plans to redeploy a portion of these savings into strategic growth initiatives, aiming to fund expansion without excessively stretching the balance sheet.

Venture Brand Momentum and Product Pipeline

Hiya and Rise Wellness remain central to USANA’s growth story, with Rise expanding Protein Pop SKUs and flavors while deepening its retail footprint. Hiya is leveraging prior brand‑building investments and early traction in North America and new international markets, and management flagged additional product innovations slated across 2026.

Core Business Year-Over-Year Declines

While venture brands are gaining momentum, management conceded that the legacy USANA nutritional business continues to post year‑over‑year sales declines. There are early signs of stabilization, but the core franchise is under pressure and has become a priority area for targeted commercial and product efforts.

High Effective Income Tax Rate Guidance

A major overhang is tax: USANA guided to an effective income tax rate between 55% and 60% for fiscal 2026. This steep burden, driven by geographic misalignment of revenue and costs and certain second‑half 2025 items, is set to materially dampen net income despite top‑line progress.

Margin and Mix Pressure from Venture Brands

Rise Wellness is expected to operate around breakeven in fiscal 2026 and carries thinner gross margins than the traditional USANA portfolio. As Rise and Hiya grow as a share of sales, the mix shift could compress consolidated gross margins, even as they contribute meaningfully to revenue growth.

Elevated Inventory and Working Capital Risk

The 48% inventory build, while strategic, heightens working capital demands and execution risk if velocity at new retailers falls short. Elevated stock levels tied to Protein Pop and Hiya’s rollout mean any demand shortfall or shelf reset could translate into markdowns or write‑downs, weighing on future profitability.

Unquantified Technology Investment and Timing Uncertainty

Management plans to accelerate technology modernization, including potential use of third‑party platforms and AI, but has not finalized scope, timing, or capital requirements. Because these incremental tech investments are excluded from the fiscal 2026 outlook, there is uncertainty around future spending and the timing of expected benefits.

Seasonality and Operational Volatility

USANA’s business remains seasonally skewed, particularly around the Lunar New Year in China, which can drive pronounced quarterly fluctuations. The shift to a 52‑week fiscal 2026, one week shorter than fiscal 2025, further complicates year‑over‑year comparisons and could obscure underlying trend lines for investors.

Forward-Looking Guidance and Outlook

Management’s guidance balances ambition with caution, anchoring on roughly 4% net sales growth for fiscal 2026, strong retail expansion for Hiya and Rise, and around $10 million in annualized cost savings. However, expectations of elevated inventories, a 55–60% effective tax rate, possible additional tech spending, and mix‑driven margin pressure underscore that execution will be critical.

USANA’s earnings call outlines a transition story: a legacy nutritional business under strain being offset by high‑potential venture brands and retail growth. Investors are left weighing tangible channel wins and returning leadership against tax headwinds, working capital risk, and thinner margins, making fiscal 2026 a pivotal year for proving this strategic pivot can translate into durable shareholder value.